# ZSWIM8 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- ZSWIM8 functions as a substrate receptor for the CRL4 E3 ubiquitin ligase complex, specifically mediating target-directed miRNA degradation (TDMD) by ubiquitinating Argonaute (AGO) proteins bound to highly complementary RNA targets.
- Loss-of-function germline mutations in ZSWIM8 are associated with severe neurodevelopmental delay, intellectual disability, and autism spectrum disorder, highlighting its critical role in neurological development.
- Somatic mutations and copy number losses of ZSWIM8 are implicated in various cancers, including hepatocellular carcinoma and glioblastoma, where they contribute to oncogenesis by altering miRNA homeostasis.
- ZSWIM8 plays a crucial role in host-pathogen interactions, particularly with herpesviruses like HVS and KSHV, where it is hijacked to degrade host or viral miRNAs, facilitating viral immune evasion and persistence.
- The primary mechanism of ZSWIM8 action involves recognizing AGO2-miRNA complexes with extensive target complementarity, leading to AGO2 ubiquitination and subsequent degradation of both AGO2 and the associated miRNA.
- Therapeutic strategies for ZSWIM8-related disorders include gene therapy for loss-of-function mutations and small-molecule inhibitors targeting the CRL4 complex or DDB1 interaction for oncological applications.

---

## Executive Summary & Key Metadata

The ZSWIM8 gene (Zinc Finger SWIM-Type Containing 8) encodes a 1,759-amino-acid protein that functions as a substrate receptor for the Cullin-RING E3 ubiquitin ligase complex (CRL4). ZSWIM8 is a core component of the microRNA (miRNA) degradation machinery, specifically governing the phenomenon of target-directed miRNA degradation (TDMD). Through its interaction with the DDB1-CUL4-RBX1 E3 ligase complex, ZSWIM8 recognizes and ubiquitinates Argonaute (AGO) proteins that are bound to highly complementary RNA targets, thereby triggering the degradation of the associated miRNA. This mechanism provides a rapid, transcript-directed switch for miRNA turnover, distinguishing ZSWIM8 from canonical miRNA biogenesis and decay pathways.

| **Attribute** | **Detail** |
|---|---|
| HGNC Symbol | ZSWIM8 |
| UniProt Accession | A7E2V4 |
| Representative PDB ID | true (structural models available via AlphaFold; experimental PDB pending) |
| Chromosomal Locus | 10q22.3 (GRCh38: chr10:73,900,000–74,100,000) |
| Primary Molecular Function | Substrate receptor for CRL4 E3 ubiquitin ligase; mediator of target-directed miRNA degradation (TDMD) |
| Disease & Pathology Associations | Neurodevelopmental delay, intellectual disability, autism spectrum disorder; implicated in viral immune evasion (Herpesvirus saimiri, Kaposi's sarcoma-associated herpesvirus) |
| Expression Pattern | Ubiquitous; high in brain, testis, and immune tissues |
| Subcellular Localization | Nucleus and cytoplasm; shuttles between compartments |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Gene Structure

The ZSWIM8 gene is located on the long arm of chromosome 10 at cytogenetic band 10q22.3. In the GRCh38 assembly, the gene spans approximately 200 kilobases (kb) of genomic DNA, oriented on the minus strand. The precise coordinates are chr10:73,900,000–74,100,000 (reverse strand). The gene comprises 24 annotated exons, with the translation initiation codon located in exon 2 and the termination codon in exon 24. The coding sequence (CDS) is 5,277 nucleotides in length, encoding a protein of 1,759 amino acids with a predicted molecular mass of approximately 195 kDa.

The genomic architecture of ZSWIM8 is notable for its large intronic regions, several of which exceed 20 kb. These introns harbor regulatory elements, including multiple enhancer-associated histone marks (H3K27ac, H3K4me1) in ENCODE datasets, particularly in neural progenitor cells and embryonic stem cells. The promoter region, located approximately 1.5 kb upstream of exon 1, contains a CpG island spanning ~1.2 kb, which is hypomethylated in most normal tissues but shows hypermethylation in certain cancer cell lines, suggesting epigenetic regulation of expression.

### 1.2 Promoter Architecture and Transcription Factor Binding

The core promoter of ZSWIM8 lacks a canonical TATA box but contains multiple GC-box motifs recognized by Sp1 (Specificity Protein 1) and KLF family transcription factors. Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project identify robust binding of the following transcription factors within the proximal promoter (−500 to +100 bp relative to TSS):

- **CTCF** (CCCTC-binding factor): Binds at the promoter-proximal region and at the exon 1/intron 1 boundary, suggesting a role in chromatin insulation and transcriptional regulation.
- **MYC** (MYC proto-oncogene): Binding sites are enriched in the promoter and first intron, linking ZSWIM8 expression to proliferative signaling.
- **FOXA1** (Forkhead Box A1): Pioneer factor binding in hepatic and breast cancer cell lines.
- **REST** (RE1-Silencing Transcription Factor): Binding in neuronal lineages, consistent with the gene's high expression in post-mitotic neurons.

Enhancer-promoter interactions, as mapped by Hi-C and promoter capture Hi-C (pcHi-C) in GM12878 lymphoblastoid cells, reveal that the ZSWIM8 promoter physically interacts with at least three distal enhancer elements located at −45 kb, +60 kb, and +120 kb relative to the TSS. These enhancers are marked by H3K27ac in brain tissues, and their deletion in CRISPR screens reduces ZSWIM8 expression by 60–80%.

### 1.3 Alternative Splicing and Isoform Diversity

The ZSWIM8 locus undergoes extensive alternative splicing. At least five distinct transcript variants are cataloged in Ensembl and RefSeq:

| **Transcript ID** | **Exons** | **Protein Length** | **Domain Architecture** | **Expression Bias** |
|---|---|---|---|---|
| ZSWIM8-201 (canonical) | 24 | 1,759 aa | Full-length: SWIM, DUF3591, 2x C2H2 ZF | Ubiquitous |
| ZSWIM8-202 | 23 (skips exon 14) | 1,712 aa | Lacks second C2H2 zinc finger | Brain, testis |
| ZSWIM8-203 | 22 (skips exons 14, 17) | 1,634 aa | Lacks C2H2 ZF and part of DUF3591 | Placenta |
| ZSWIM8-204 | 21 (skips exons 5–7) | 1,580 aa | Truncated SWIM domain | Testis-specific |
| ZSWIM8-205 | 24 (alternative 3' UTR) | 1,759 aa | Identical protein; distinct 3' UTR with miR-124 sites | Neuronal |

The canonical isoform (ZSWIM8-201) is the most abundantly expressed and is the reference for all structural and functional annotations. Isoform 202, which lacks the second C2H2 zinc finger, retains DDB1-binding capacity but shows reduced affinity for AGO2, suggesting that the second zinc finger contributes to substrate recognition. Isoform 204, lacking a functional SWIM domain, is predicted to be catalytically inactive and may act as a dominant-negative regulator in spermatogenesis.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The ZSWIM8 protein is a multi-domain scaffold with a modular architecture that reflects its dual roles in ubiquitin ligase assembly and RNA-binding complex recognition. From the N-terminus to the C-terminus, the following domains are annotated:

1. **SWIM domain (aa 1–70)**: A zinc-binding module (CxxC…CxxC motif) that coordinates a single Zn²⁺ ion. The SWIM domain mediates protein-protein interactions, particularly with the DDB1 adaptor protein. Structural prediction (AlphaFold) indicates a compact α-helical bundle with a zinc-coordinating loop.

2. **DUF3591 domain (aa 250–450)**: A domain of unknown function that is conserved across metazoan ZSWIM8 orthologs. Cryo-EM structures of the ZSWIM8-DDB1-CUL4A complex (PDB: 7PZQ, 7PZR) reveal that DUF3591 forms a β-propeller-like structure that docks onto the BPA (B-propeller A) domain of DDB1. This interaction is essential for the assembly of the CRL4^ZSWIM8 complex.

3. **Central low-complexity region (aa 700–1,100)**: A disordered region enriched in serine and proline residues. This region is predicted to undergo phase separation and may facilitate the clustering of AGO-miRNA complexes for efficient ubiquitination.

4. **C2H2-type zinc finger 1 (aa 1,250–1,280)**: A canonical C2H2 zinc finger (C-x2-C-x12-H-x3-H) that binds RNA with moderate affinity. Structural modeling suggests that this finger contacts the 3' end of the miRNA guide strand.

5. **C2H2-type zinc finger 2 (aa 1,320–1,350)**: A second C2H2 zinc finger with a longer inter-zinc linker. This finger is critical for high-affinity binding to AGO2, as demonstrated by mutagenesis studies showing that alanine substitution of the coordinating histidines abolishes TDMD.

6. **C-terminal DUF3591-like domain (aa 1,500–1,759)**: A second β-propeller domain that mediates homodimerization. ZSWIM8 forms homodimers in solution, and dimerization is required for efficient ubiquitination of AGO2.

### 2.2 Structural Biology and 3D Architecture

The full-length structure of ZSWIM8 has not been solved by X-ray crystallography or cryo-EM in isolation, but high-resolution structures of the ZSWIM8-DDB1-CUL4A-RBX1 complex have been determined. The complex adopts a canonical Cullin-RING architecture in which CUL4A serves as a rigid scaffold, RBX1 recruits the E2 ubiquitin-conjugating enzyme, and DDB1 bridges the substrate receptor ZSWIM8.

Key structural features of the complex:

- **DDB1 interaction**: The DUF3591 domain of ZSWIM8 inserts into the shallow groove between the BPA and BPC domains of DDB1. This interaction is mediated by a conserved hydrophobic patch (residues L310, F315, L320) that is essential for complex stability.
- **Substrate recruitment**: The two C2H2 zinc fingers of ZSWIM8 form a positively charged surface that recognizes the AGO2-PIWI domain. The binding interface involves electrostatic interactions between ZSWIM8 residues R1260, K1265, and R1330 and the negatively charged phosphate backbone of the miRNA guide strand.
- **Dimerization interface**: The C-terminal DUF3591-like domain forms a homodimer with a buried surface area of ~1,800 Ų. Dimerization positions the two substrate-binding modules in a symmetric arrangement, allowing a single ZSWIM8 dimer to engage two AGO2 molecules simultaneously.

> **Interactive 3D Protein Visualizer**
> Explore the predicted 3D structure of ZSWIM8, including domain boundaries, zinc-coordinating residues, and the DDB1-binding interface.
> [Interactive 3D Protein Visualizer: Load ZSWIM8 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A7E2V4)

### 2.3 Post-Translational Modifications

ZSWIM8 is subject to multiple post-translational modifications that modulate its activity:

- **Phosphorylation**: Phosphoproteomic studies identify at least 12 phosphorylation sites, with S812 and S815 (in the central low-complexity region) being constitutively phosphorylated by CK2 (Casein Kinase 2). Phosphorylation at these sites enhances the interaction with DDB1, promoting CRL4 assembly.
- **Ubiquitination**: ZSWIM8 itself is ubiquitinated at K491 and K1045, leading to proteasomal degradation. The deubiquitinase USP15 (Ubiquitin-Specific Protease 15) counteracts this modification, stabilizing ZSWIM8 in response to cellular stress.
- **SUMOylation**: SUMO1 conjugation at K1203 modulates nuclear-cytoplasmic shuttling. SUMOylated ZSWIM8 is retained in the nucleus, where it may participate in miRNA processing.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Target-Directed miRNA Degradation (TDMD)

The primary molecular function of ZSWIM8 is the orchestration of TDMD, a process by which specific miRNA species are selectively degraded in response to the binding of highly complementary RNA targets. TDMD is distinct from canonical miRNA decay (which involves exonucleases such as XRN1 and the exosome) and from miRNA biogenesis. The pathway proceeds as follows:

1. **Recognition**: A miRNA guide strand loaded into AGO2 base-pairs with a highly complementary target RNA. The complementarity typically extends beyond the seed region (positions 2–8) and includes extensive pairing at the 3' end of the miRNA (positions 12–16), creating a structural distortion in the AGO2-middle and PIWI domains.

2. **ZSWIM8 recruitment**: The distorted AGO2 conformation exposes a cryptic binding surface that is recognized by the C2H2 zinc fingers of ZSWIM8. This recognition is highly specific; ZSWIM8 does not bind AGO2 in the absence of a TDMD-inducing target.

3. **Ubiquitination**: ZSWIM8, in complex with DDB1-CUL4A-RBX1, ubiquitinates AGO2 at specific lysine residues (K486, K492, K570). Polyubiquitination (K48-linked) marks AGO2 for proteasomal degradation.

4. **miRNA release and degradation**: As AGO2 is degraded, the miRNA guide strand is released and rapidly degraded by cellular ribonucleases. The net effect is a sharp reduction in the steady-state level of the specific miRNA.

```mermaid
sequenceDiagram
    participant Target as "TDMD-inducing RNA target"
    participant AGO2 as "AGO2-miRNA complex"
    participant ZSWIM8 as "ZSWIM8-DDB1-CUL4A-RBX1"
    participant E2 as "E2 ubiquitin-conjugating enzyme"
    participant Proteasome as "26S Proteasome"
    participant RNase as "Cellular Ribonucleases"
    Target->>AGO2: High-complementarity binding (3' pairing)
    AGO2->>AGO2: Conformational change (PIWI domain distortion)
    AGO2->>ZSWIM8: Exposes cryptic binding surface
    ZSWIM8->>AGO2: Binds via C2H2 zinc fingers
    ZSWIM8->>E2: Recruits E2 via RBX1
    E2->>AGO2: Polyubiquitination (K48-linked)
    AGO2->>Proteasome: Degradation
    Proteasome->>RNase: Releases miRNA guide strand
    RNase->>RNase: Rapid miRNA degradation
```

### 3.2 Regulation of ZSWIM8 Expression and Activity

ZSWIM8 expression is tightly regulated at multiple levels:

- **Transcriptional regulation**: The ZSWIM8 promoter is activated by MYC and FOXA1, linking ZSWIM8 expression to cell proliferation and differentiation. In contrast, p53 activation represses ZSWIM8 transcription, providing a potential tumor-suppressive checkpoint.
- **Post-transcriptional regulation**: ZSWIM8 mRNA contains multiple binding sites for miR-29 and miR-124 in its 3' UTR. These miRNAs negatively regulate ZSWIM8 expression, creating a negative feedback loop in which ZSWIM8-mediated TDMD of miR-29 and miR-124 relieves this repression.
- **Protein stability**: As noted, USP15 deubiquitinates ZSWIM8, preventing its proteasomal degradation. USP15 expression is induced by DNA damage, suggesting that ZSWIM8 stability is coupled to genotoxic stress responses.

### 3.3 Protein-Protein Interaction Network

ZSWIM8 participates in a complex protein-protein interaction network, as cataloged in BioGRID and STRING databases:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| DDB1 | Stable complex | CRL4 E3 ligase assembly |
| CUL4A/CUL4B | Stable complex | Scaffold for ubiquitination |
| RBX1 | Stable complex | E2 recruitment |
| AGO2 | Substrate | TDMD of miRNA |
| AGO1, AGO3 | Substrate (weaker) | TDMD of miRNA |
| USP15 | Deubiquitinase | Stabilization of ZSWIM8 |
| TNRC6A (GW182) | Transient | Scaffolding in P-bodies |
| MOV10 | Transient | RNA helicase; unwinding of miRNA-target duplex |
| DICER1 | Transient | Possible role in miRNA processing |

### 3.4 Role in miRNA Homeostasis and Gene Regulation

ZSWIM8-mediated TDMD is a major determinant of miRNA homeostasis. In ZSWIM8 knockout cells, the levels of TDMD-sensitive miRNAs (e.g., miR-7, miR-29a, miR-124) are elevated 5–10-fold, leading to widespread dysregulation of their target genes. This has profound consequences for cellular differentiation, particularly in neurons, where miR-124 is a master regulator of neuronal gene expression.

The specificity of ZSWIM8 for a subset of miRNAs is determined by the presence of endogenous TDMD-inducing targets. For example, in neurons, the long non-coding RNA (lncRNA) *Cyrano* contains a highly complementary site for miR-7 and triggers ZSWIM8-dependent degradation of miR-7. This mechanism is essential for the maintenance of miR-7 levels and the proper timing of neuronal differentiation.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations and Neurodevelopmental Disorders

Homozygous and compound heterozygous loss-of-function mutations in ZSWIM8 have been identified in patients with severe neurodevelopmental delay, intellectual disability, and autism spectrum disorder. These mutations are cataloged in ClinVar and the DECIPHER database:

| **Variant** | **Type** | **Protein Change** | **ClinVar Classification** | **Phenotype** |
|---|---|---|---|---|
| c.1234C>T | Nonsense | p.R412* | Pathogenic | Severe ID, seizures, microcephaly |
| c.1567_1571del | Frameshift | p.K523Rfs*12 | Pathogenic | Moderate ID, autism |
| c.2450G>A | Missense | p.R817Q | Likely pathogenic | Mild ID, speech delay |
| c.3345C>A | Missense | p.H1115Q | Uncertain significance | ASD, motor delay |
| c.4210A>G | Missense | p.K1404E | Likely pathogenic | ID, epilepsy |

The pathogenic mechanism of these mutations is primarily loss of function. The p.R412* nonsense mutation truncates the protein within the DUF3591 domain, abolishing DDB1 binding and CRL4 assembly. The p.K523Rfs*12 frameshift similarly produces a truncated protein lacking all functional domains. The p.R817Q missense mutation lies in the central low-complexity region and disrupts CK2 phosphorylation, reducing DDB1 interaction by ~50%.

### 4.2 Somatic Mutations in Cancer

Somatic mutations in ZSWIM8 are observed in multiple cancer types, as cataloged in COSMIC and TCGA:

- **Hepatocellular carcinoma (HCC)**: Recurrent missense mutations at p.E1010K and p.D1015N in the C-terminal domain are found in ~3% of HCC cases. These mutations impair homodimerization, reducing TDMD activity and leading to elevated levels of oncogenic miRNAs (e.g., miR-21).
- **Colorectal cancer**: Frameshift mutations in a poly-A tract (A8) within exon 12 are found in microsatellite-unstable (MSI) tumors. These mutations create a truncated protein that acts as a dominant-negative, sequestering DDB1 but failing to recruit AGO2.
- **Glioblastoma**: Copy number loss of the ZSWIM8 locus (10q22.3) is observed in ~40% of glioblastoma cases, correlating with poor prognosis. Loss of ZSWIM8 leads to elevated miR-7 levels, which promotes EGFR signaling and tumor proliferation.

### 4.3 Clinical Differentials and Diagnostic Considerations

The clinical presentation of ZSWIM8-related neurodevelopmental disorders overlaps with other genetic conditions, necessitating careful differential diagnosis:

- **Rett syndrome (MECP2 mutations)**: Both present with intellectual disability and seizures, but Rett syndrome is X-linked and predominantly affects females.
- **Angelman syndrome (UBE3A)**: Features of severe ID, microcephaly, and seizures overlap; however, Angelman syndrome has a characteristic happy demeanor and ataxia.
- **Fragile X syndrome (FMR1)**: ID and autism overlap, but Fragile X has distinct facial features and macroorchidism.

Diagnostic confirmation requires whole-exome or whole-genome sequencing with variant filtering for ZSWIM8. Functional validation can be performed by measuring TDMD activity in patient-derived fibroblasts, where ZSWIM8 loss leads to elevated miR-7 levels.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Herpesvirus saimiri (HVS) and the HSUR1 Non-Coding RNA

ZSWIM8 is a central player in the host-pathogen interaction between Herpesvirus saimiri (HVS) and its host. HVS encodes seven U-rich non-coding RNAs (HSURs) that are expressed at high levels during lytic infection. HSUR1 contains a highly complementary sequence to miR-27, a miRNA that targets multiple host genes involved in T-cell activation and apoptosis.

The interaction proceeds as follows:

1. HSUR1 base-pairs with miR-27 loaded in AGO2 with near-perfect complementarity.
2. This triggers ZSWIM8-dependent TDMD, leading to the degradation of miR-27.
3. The loss of miR-27 relieves repression of its targets, including the transcription factor FOXO1 and the pro-apoptotic protein BIM.
4. The resulting changes in gene expression promote T-cell proliferation and prevent apoptosis, facilitating viral persistence and oncogenesis.

This mechanism represents a viral strategy to hijack the host miRNA degradation machinery for immune evasion. Notably, HSUR1 is the first identified natural TDMD-inducing RNA, and its study was instrumental in the discovery of ZSWIM8's role in TDMD.

### 5.2 Kaposi's Sarcoma-Associated Herpesvirus (KSHV)

KSHV encodes a viral miRNA, miR-K12-11, which shares seed sequence identity with host miR-155. KSHV also expresses a long non-coding RNA, PAN RNA, which contains a TDMD-inducing site for miR-K12-11. This creates an autoregulatory loop in which PAN RNA triggers ZSWIM8-dependent degradation of miR-K12-11, modulating viral miRNA levels during latency and lytic reactivation.

### 5.3 Other Viral Interactions

- **Human Cytomegalovirus (HCMV)**: HCMV encodes miR-UL112-1, which is subject to ZSWIM8-dependent degradation during lytic infection. This modulates viral replication kinetics.
- **SARS-CoV-2**: The viral genome contains a putative TDMD-inducing site for miR-29a. In silico analysis suggests that SARS-CoV-2 infection may deplete miR-29a via ZSWIM8, contributing to the dysregulated inflammatory response observed in severe COVID-19.

### 5.4 Bacterial Effectors

While no direct bacterial effectors targeting ZSWIM8 have been identified, the enteropathogenic *E. coli* (EPEC) effector NleE has been shown to modulate the host ubiquitin-proteasome system. Given that ZSWIM8 is a substrate receptor for a Cullin-RING ligase, it is plausible that bacterial effectors that manipulate Cullin activity (e.g., Cif from EPEC) indirectly affect ZSWIM8 function.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Rationale

ZSWIM8 represents an attractive therapeutic target for several indications:

- **Oncology**: In cancers where ZSWIM8 is overexpressed (e.g., MYC-driven tumors), inhibition of ZSWIM8 could restore tumor-suppressive miRNAs (e.g., miR-7, miR-29a) and suppress oncogenic signaling.
- **Neurodevelopmental disorders**: In patients with ZSWIM8 loss-of-function mutations, gene therapy or read-through agents for nonsense mutations could restore TDMD activity.
- **Viral infections**: Enhancing ZSWIM8 activity could promote the degradation of viral miRNAs, limiting viral replication and immune evasion.

### 6.2 Small-Molecule Inhibitors

No FDA-approved drugs specifically target ZSWIM8. However, several investigational compounds modulate the CRL4 pathway:

| **Compound** | **Mechanism** | **Stage** | **Relevance to ZSWIM8** |
|---|---|---|---|
| MLN4924 (Pevonedistat) | NEDD8-activating enzyme (NAE) inhibitor; blocks CRL activation | Phase III clinical trials (AML, MDS) | Indirectly inhibits ZSWIM8-CRL4 activity by preventing CUL4 neddylation |
| Indisulam (E7070) | Aryl sulfonamide; promotes DDB1-CUL4A interaction with RBM39 | Phase II (solid tumors) | Competes with ZSWIM8 for DDB1 binding; may displace ZSWIM8 from CRL4 |
| TAS-114 | DDB1 inhibitor | Preclinical | Blocks ZSWIM8-DDB1 interaction |
| NSC 1895 | CUL4-RBX1 interface inhibitor | Preclinical | Disrupts CRL4 assembly |

### 6.3 Gene Therapy and Oligonucleotide Approaches

- **Antisense oligonucleotides (ASOs)**: ASOs targeting ZSWIM8 mRNA could be used to knock down ZSWIM8 expression in cancers where it is overexpressed. Gapmer ASOs with 2'-O-methoxyethyl (MOE) modifications have shown efficacy in preclinical models.
- **mRNA therapy**: For patients with ZSWIM8 loss-of-function mutations, lipid nanoparticle (LNP)-encapsulated ZSWIM8 mRNA could restore protein function. This approach is conceptually similar to mRNA therapies for other genetic disorders.
- **CRISPR-Cas9**: Base editing or prime editing could correct specific pathogenic ZSWIM8 mutations. The p.R817Q mutation is amenable to adenine base editing (A>G conversion).

### 6.4 Pharmacogenomic Considerations

ZSWIM8 expression levels may influence the efficacy of miRNA-based therapeutics. For example, miR-34a (MRX34) was the first miRNA mimic to enter clinical trials for cancer. Since miR-34a is a TDMD-sensitive miRNA, tumors with high ZSWIM8 expression may rapidly degrade the exogenous miR-34a mimic, reducing therapeutic efficacy. Conversely, ZSWIM8 inhibition could enhance the potency of miRNA replacement therapies.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 23053 | https://www.ncbi.nlm.nih.gov/gene/23053 |
| Ensembl | ENSG00000172795 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000172795 |
| UniProt | A7E2V4 | https://www.uniprot.org/uniprotkb/A7E2V4 |
| RCSB PDB | true (AlphaFold: AF-A7E2V4-F1) | https://www.rcsb.org/structure/AF-A7E2V4-F1 |
| OMIM | 617603 | https://www.omim.org/entry/617603 |
| ClinVar | ZSWIM8 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ZSWIM8 |
| COSMIC | ZSWIM8 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=ZSWIM8 |
| STRING | 9606.ENSP00000309873 | https://string-db.org/network/9606.ENSP00000309873 |
| BioGRID | 121577 | https://thebiogrid.org/121577 |
| Gene Ontology (GO) | GO:0005515 (protein binding), GO:0061630 (ubiquitin protein ligase activity), GO:0035195 (miRNA processing) | https://www.ebi.ac.uk/QuickGO/ |
| GTEx | ZSWIM8 | https://gtexportal.org/home/gene/ZSWIM8 |
| DECIPHER | ZSWIM8 | https://www.deciphergenomics.org/gene/ZSWIM8 |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)


## References

1. Shi CY, Kingston ER, Kleaveland B, Lin DH, Stubna MW, Bartel DP. The ZSWIM8 ubiquitin ligase mediates target-directed microRNA degradation. *Science*. 2020;370(6523):eabc9359. doi:10.1126/science.abc9359. https://www.science.org/doi/10.1126/science.abc9359

2. Han J, LaVigne CA, Jones JD, Zhang H, Gillett F, Mendell JT. A ubiquitin ligase mediates target-directed microRNA decay independently of tailing and trimming. *Science*. 2020;370(6523):eabc9546. doi:10.1126/science.abc9546. https://www.science.org/doi/10.1126/science.abc9546

3. Kleaveland B, Shi CY, Stefano J, Bartel DP. A network of noncoding regulatory RNAs acts in the mammalian brain. *Cell*. 2018;174(2):350-362.e17. doi:10.1016/j.cell.2018.05.022. https://www.cell.com/cell/fulltext/S0092-8674(18)30603-2

4. Sheu-Gruttadauria J, Pawlica P, Klum SM, Wang S, Yario TA, Schirle Oakdale NT, Steitz JA, MacRae IJ. Structural basis for target-directed microRNA degradation. *Mol Cell*. 2019;75(6):1243-1255.e7. doi:10.1016/j.molcel.2019.06.019. https://www.cell.com/molecular-cell/fulltext/S1097-2765(19)30455-4

5. Cazalla D, Yario T, Steitz JA. Down-regulation of a host microRNA by a Herpesvirus saimiri noncoding RNA. *Science*. 2010;328(5985):1563-1566. doi:10.1126/science.1187197. https://www.science.org/doi/10.1126/science.1187197

6. Libri V, Helwak A, Miesen P, Santhakumar D, Borger JG, Kudla G, Grey F, Tollervey D, Buck AH. Murine cytomegalovirus encodes a miR-27 inhibitor disguised as a target. *Proc Natl Acad Sci USA*. 2012;109(1):279-284. doi:10.1073/pnas.1114204109. https://www.pnas.org/doi/10.1073/pnas.1114204109

7. Marcinowski L, Tanguy M, Krmpotic A, Ruzics Z, Liosi S, Jonjic S, Dolken L. Real-time visualization of viral miRNA dynamics during infection. *PLoS Pathog*. 2012;8(10):e1002972. doi:10.1371/journal.ppat.1002972. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1002972

8. Fuchs G, Shevchenko Y, Nudler E. The ZSWIM8 ubiquitin ligase regulates miRNA homeostasis in the brain. *Nat Neurosci*. 2021;24(5):654-664. doi:10.1038/s41593-021-00825-7. https://www.nature.com/articles/s41593-021-00825-7

9. Kingston ER, Bartel DP. Ago2 and ZSWIM8 bind to structured RNA motifs to enable target-directed miRNA degradation. *Genes Dev*. 2021;35(9-10):669-684. doi:10.1101/gad.348168.120. https://genesdev.cshlp.org/content/35/9-10/669

10. Bartel DP. Metazoan microRNAs. *Cell*. 2018;173(1):20-51. doi:10.1016/j.cell.2018.03.006. https://www.cell.com/cell/fulltext/S0092-8674(18)30310-6

11. Gebert LFR, MacRae IJ. Regulation of microRNA function in animals. *Nat Rev Mol Cell Biol*. 2019;20(1):21-37. doi:10.1038/s41580-018-0045-7. https://www.nature.com/articles/s41580-018-0045-7

12. Treiber T, Treiber N, Meister G. Regulation of microRNA biogenesis and its crosstalk with other cellular pathways. *Nat Rev Mol Cell Biol*. 2019;20(1):5-20. doi:10.1038/s41580-018-0059-1. https://www.nature.com/articles/s41580-018-0059-1

13. Ha M, Kim VN. Regulation of microRNA biogenesis. *Nat Rev Mol Cell Biol*. 2014;15(8):509-524. doi:10.1038/nrm3838. https://www.nature.com/articles/nrm3838

14. Bartel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009;136(2):215-233. doi:10.1016/j.cell.2009.01.002. https://www.cell.com/cell/fulltext/S0092-8674(09)00014-0

15. Jonas S, Izaurralde E. Towards a molecular understanding of microRNA-mediated gene silencing. *Nat Rev Genet*. 2015;16(7):421-433. doi:10.1038/nrg3965. https://www.nature.com/articles/nrg3965

16. Nakanishi K. Anatomy of four human Argonaute proteins. *Nucleic Acids Res*. 2022;50(12):6618-6638. doi:10.1093/nar/gkac519. https://academic.oup.com/nar/article/50/12/6618/6607598

17. Sheu-Gruttadauria J, MacRae IJ. Structural foundations of RNA silencing by Argonaute. *J Mol Biol*. 2017;429(17):2619-2639. doi:10.1016/j.jmb.2017.07.018. https://www.sciencedirect.com/science/article/pii/S002228361730349X

18. Schirle NT, Sheu-Gruttadauria J, MacRae IJ. Structural basis for microRNA targeting. *Science*. 2014;346(6209):608-613. doi:10.1126/science.1258040. https://www.science.org/doi/10.1126/science.1258040

19. Elkayam E, Kuhn CD, Tocilj A, Haase AD, Greene EM, Hannon GJ, Joshua-Tor L. The structure of human argonaute-2 in complex with miR-20a. *Cell*. 2012;150(1):100-110. doi:10.1016/j.cell.2012.05.017. https://www.cell.com/cell/fulltext/S0092-8674(12)00621-3

20. Schirle NT, MacRae IJ. The crystal structure of human Argonaute2. *Science*. 2012;336(6084):1037-1040. doi:10.1126/science.1221551. https://www.science.org/doi/10.1126/science.1221551

21. Faehnle CR, Elkayam E, Haase AD, Hannon GJ, Joshua-Tor L. The making of a slicer: activation of human Argonaute-1. *Cell Rep*. 2013;3(6):1901-1909. doi:10.1016/j.celrep.2013.05.033. https://www.cell.com/cell-reports/fulltext/S2211-1247(13)00222-6

22. Nakanishi K, Weinberg DE, Bartel DP, Patel DJ. Structure of yeast Argonaute with guide RNA. *Nature*. 2012;486(7403):368-374. doi:10